RTTNews | Jan 5, 2022 07:35AM EST

07:35 Wednesday, January 5, 2022 (RTTNews.com) - Moderna, Inc. (MRNA) said the first participant has been dosed in the phase 1 study of mRNA-1189, the company's Epstein-Barr Virus vaccine candidate. The phase 1 randomized, observer-blind, placebo-controlled study of mRNA-1189 will be conducted at approximately 15 sites in the U.S. The primary purpose of the study is to assess safety and tolerability of mRNA-1189 in healthy adults ages 18 to 30. Moderna expects to enroll approximately 270 participants.

Moderna's vaccine candidate against Epstein-Barr Virus (mRNA-1189) is being developed to prevent EBV-induced infectious mononucleosis and potentially Epstein-Barr Virus infection.

Read the original article on RTTNews ( https://www.rttnews.com/3252918/moderna-begins-phase-1-study-of-its-epstein-barr-virus-vaccine-candidate.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved